Tumors (n = 16) features | SQ Sodium MRI | IR Sodium MRI | % difference | Â | |||
---|---|---|---|---|---|---|---|
signal intensity A.U. | concentration (mM) | signal intensity A.U. | concentration (mM) | SQ | IR | Mitotic figures (per HPF) | |
Contol Phantom: | 9.5 ± 0.3 | 100 | 4.2 ± 0.5 | 10 |  |  |  |
Day 1(0 hour): | Â | Â | Â | Â | Â | Â | Â |
Control(n = 41)sites | 5.6 ± 0.2 | 58.9 ± 2.1 | 4.5 ± 0.1 | 10.7 ± 1.0 |  |  |  |
Sham(n = 40)sites | 5.5 ± 0.6 | 57.8 ± 6.3 | 4.6 ± 0.2 | 10.9 ± 2.1 | 1.7 ± 0.5 |  |  |
Water placebo(n = 40) | 5.9 ± 0.8 | 62.0 ± 8.4 | 3.3 ± 0.3 | 7.8 ± 0.7 | 5.3 ± 2 |  |  |
Pre-treatment | Â | Â | Â | Â | Â | Â | Â |
Tumor regions (n = 160 sites) |  |  |  |  |  |  | 2.4 ± 0.6 |
Viable | 6.8 ± 1.1 | 71.5 ± 11.6 | 6.1 ± 0.8 | 14.5 ± 1.9 |  |  |  |
Active necrosis | 7.6 ± 1.4 | 79.9 ± 9.4 | 8.6 ± 1.0 | 20.5 ± 2.4 |  |  |  |
Apoptosis | 6.2 ± 0.9 | 65.2 ± 9.2 | 10.8 ± 1.2 | 26 ± 3 |  |  |  |
Cyst | 19.5 ± 2.3 | 205.1 ± 24.2 | 7.2 ± 0.7 | 17.1 ± 1.6 |  |  |  |
*Apoptosis | 6.2 ± 1.6 | 65.2 ± 16.8 | 10.3 ± 1.4 | 24.5 ± 3.3 |  |  |  |
Day 2(24 hours): | Â | Â | Â | Â | Â | Â | Â |
Control(n = 41)sites | 4.7 ± 0.2 | 49.4 ± 2.1 | 3.5 ± 0.4 | 8.3 ± 0.9 | 16.0 ± 0.2 | 22 ± 0.6 |  |
Sham(n = 40)sites | 6.8 ± 0.8 | 71.5 ± 8.4 | 4.2 ± 1.1 | 10 ± 2.6 | 23.6 ± 3.3 | 8.6 ± 0.8 |  |
Taxotere injected (n = 40 sites) | 7.9 ± 0.4 | 83.1 ± 4.2 | 5.0 ± 0.4 | 11.9 ± 0.9 | 33.8 ± 0.5 | 51.5 ± 3.3 |  |
24 hr Post treated | Â | Â | Â | Â | Â | Â | Â |
Tumor regions (n = 160 sites) |  |  |  |  |  |  | 8.5 ± 0.5 |
Viable | 6.2 ± 1.6 | 65.2 ± 16.8 | 7.6 ± 1.2 | 18.0 ± 2.8 | 8.8 ± 0.5 | 24.5 ± 0.4 |  |
Active necrosis | 6.8 ± 1.2 | 71.5 ± 12.6 | 9.1 ± 1.0 | 21.6 ± 2.4 | 10.5 ± 1.4 | 5.8 ± 0.5 |  |
Apoptosis | 6.4 ± 0.9 | 67.3 ± 9.2 | 18.8 ± 1.7 | 44.7 ± 4.0 | 3.2 ± 0.0 | 74.0 ± 4.1 |  |
Cyst | 22.6 ± 2.6 | 237.7 ± 27.3 | 6.2 ± 1 | 14.7 ± 4.3 | 15.9 ± 1.3 | 13.8 ± 0.58 |  |